netFormulary NHS
Coastal West Sussex
Local Health Economy Formulary
 Search
News
News Title
news

May 2020 - Revised CWS Cannabis Prescribing Position Statement:

A revised position statement on the use of cannabis based products within CWS is now available on the CWS website  - CWS cannabis prescribing position statement 2020

    
24/06/2020
   
news

March 2020 - Regular prescribing quantities are NOT to be increased during the Covid-19 crisis:

Clinicians are reminded that prescribed quantities of medication should not be increased during the current Covid-19 crisis.

Patients may well request a larger supply than normal but this should be declined and they should be advised that requesting repeat prescriptions at their usual intervals and for their usual quantities will minimise the chances of the supply chain being disrupted, so all patients can continue to obtain their medication.

    
25/03/2020
   
news

March 2020 - Revised CWS Interface Prescribing Policy:

The latest version is now available to access on the Coastal West Sussex Formulary and Coastal West Sussex website.

    
20/03/2020
   
news

February 2020 - RMOC Position Statement on Oral Vitamin B Supplementation in Alcoholism:

SPfT are revising their guidance to align with this new Regional Medicines Optimisation Committee (RMOC) guidance, and it was agreed at the CWS Area Prescribing Committee meeting in January, that CWS would adopt this RMOC position statement. It is also available to access on the CWS formulary linked to oral Vitamin B products.

    
20/03/2020
   
news

January 2020 - Biomelatonin update:

Pharma Nord have discontinued their supply of “Bio-melatonin®” in the UK, and have brought out a new licensed melatonin in its place. It is only licensed for treatment of jet lag in adults, (the same as the recently released Colonis brand melatonin) and is not recommended for use in patients under 18 years old. This means that we now need to use a licensed product in an “off licence” way.

Further discussions are required to decide the best way forward for prescribing this treatment, but in the meantime, it was agreed that the new Pharma-Nord melatonin should be used in place of Bio-melatonin®.

    
20/03/2020
   
news

November 2019 - Managing females of child bearing potential (FCBP) prescribed valproate at the primary/secondary care interface:

  • A primary/secondary care interface document for managing females of child bearing potential (FCBP) prescribed valproate is now available here. It includes a form for patients to complete and sign to acknowledge the potential risks if they are unwilling to engage in the annual review process, but request that their sodium valproate continues to be prescribed.
    
17/12/2019
   
news

October 2019 – Denosumab (Prolia®) injections:

  • For patients being initiated on denosumab (Prolia®) injections, WSHfT have always administered at least the first two injections before transferring prescribing/administration responsibility to primary care. It was agreed by the Area Prescribing Committee that this be amended to at least the first injection, to free up clinical time for the osteoporosis nurses to see more new patients and undertake more DEXA scan reporting.

    
22/10/2019
   
news

September 2019 - Updated melatonin prescribing guidance:

  • A recent situation regarding a new melatonin product (licensed only for jet lag in adults) has caused confusion and disruption between patients, prescribers and pharmacies. CWS CCG has issued a letter providing clarification and guidance for all CWS prescribers, which is available here.

    
22/10/2019
   
news

August 2019 - Availability of Emerade 0.3mg and Emerade 0.5mg Adrenaline Auto-Injectors:

Emerade (adrenaline auto-injector devices) will be subject to short term disruption to supply.  The manufacturer (Bausch & Lomb) states:

  • Emerade 500 microgram is out of stock until the 28 August 2019.
  • Emerade 300 microgram has limited supplies remaining but will be out of stock from early-mid August with further supplies expected by 30 September 2019.

Supply disruption alert from the Department of Health and Social Care

MHRA Adrenaline auto-injectors: updated advice after European review

If an alternative brand is prescribed,  the patient or carer will need to be trained on how to administer the new auto-injector.
    
02/08/2019
   
news

June 2019 - Revised continence formulary:

    
25/06/2019
   
news

May 2019 - Revised CWS Position Statement regarding Freestyle Libre®:

    
10/06/2019
   
news

April 2019 – Labetalol tablets (all strengths) supply issue:

  • DHSC has been made aware of a supply issue for all strengths of labetalol tablets and as a result, supplies will be very limited from April until early-mid May. Prescribers should be aware that no new patients should be commenced on labetalol during this time. Patients who do not have sufficient supplies to last until early May and who are unable to obtain supplies of labetalol will need to be switched to an appropriate alternative treatment during this time. Link to full article on CWS CCG website

    
16/04/2019
   
news

April 2019 – Levomepromazine 25mg/ml injection supply issue:

  • Sanofi informed NHS England and DHSC on 5th April 2019 that they are going out of stock this week of levomepromazine 25mg/ml injection and new stock is expected to be available from the end of April. The only other UK supplier, Wockhardt, have informed us that due to the unexpected increase in demand, they will also go out of stock of levomepromazine injection, with further stock expected at the end of April. Wockhardt have confirmed the remaining stock which is held at Alliance will be ring-fenced for primary care use only. Stock at Alliance is limited and will not last until the end of April. Link to full article on CWS CCG website
    
16/04/2019
   
news

February 2019 - Discontinuation of Cilest® :

  • The manufacturer of Cilest® (norgestimate and ethinyl estradiol) has advised that it will be discontinued in July 2019. They state that this was a commercial decision and stressed that there are no safety, efficacy or quality issues with the product. Current supplies are expected to last until mid-July 2019. Cilique® and Lizinna® have been added to the CWS formulary to replace Cilest® as direct comparables.

    
04/03/2019
   
news

January 2019 - CWS APC cannabis based products position statement:

    
04/02/2019
   
news

December 2018 - Community Nurses collecting and transporting injectable medicines:

  • Until now, community nurses have been collecting prescribed injectable medicines and transporting them to the patient's home for administration. Due to workload pressures, it was agreed at the November 18 APC meeting that going forward, these items should be prescribed, dispensed and delivered along with patient's other medications, so they are already at the patient's home when the nurse visits. 
    
16/01/2019
   
news

November 2018 - Shortage of Bricanyl® Turbohaler:

  • Astra Zeneca UK Ltd, the manufacturer of Bricanyl® Turbohaler® have informed healthcare professionals that they are currently experiencing an interruption to normal supplies. This is resulting in a temporary stock shortage and although some stock will be available in December 2018  the stock shortage is unlikely to fully resolve until end of January 2019. UKMi memo
    
04/12/2018
   
news

October 2018 - Reclassification of gabapentinoids:

  • Following a public consultation and advice from the Advisory Council on the Misuse of Drugs, from April 2019 pregabalin and gabapentin will become controlled drugs and be placed under Schedule 3 of the Misuse of Drugs Regulations 2001 and Class C of the Misuse of Drugs Act 1971. Prescriptions of pregabalin and gabapentin will be limited to 30 days’ treatment, repeat prescriptions will not be issued and any prescription must be dispensed with 28 days. Link to Gov.Uk statement

    
26/11/2018
   
news

September 2018 - Availability of EpiPen 0.3mg and EpiPen JR 0.15mg Adrenaline Auto-Injectors:

EpiPen and EpiPen Junior (adrenaline auto-injector devices) will be subject to limited availability for the remainder of 2018.  The manufacturer (Mylan) are currently out of stock of EpiPen Junior, with continued interruptions in supply anticipated in the coming months.
Supply disruption alert from the Department of Health and Social Care.

  • There is currently a temporary unavailability of EpiPen JR 0.15mg auto-injectors. Please use an alternative adrenaline auto-injector, though the patient or carer will need to be trained on how to administer the new auto-injector.
  • There is currently limited stock availability of the EpiPen 0.3mg auto-injectors. There are short dated stocks (Feb 2019) which community pharmacies can order through their usual channels. Stock with a longer expiry date is limited to two auto-injectors per prescription and community pharmacies should refer to the instructions within the link below.    27th September 2018 Update - EpiPen and EpiPen Junior 
    
01/10/2018
   
news

August 2018 - Rifaximin for treating hepatic encephalopathy:

  • The recoding of Rifaximin (Targaxin®) tablets on the CWS formulary from RED to BLUE was agreed at the July 2018 APC meeting. A Rifaximin (Targaxin®) blue coding information sheet is now available to access on the CWS website and the CWS local health economy formulary.
    
14/09/2018
   
news

July 2018 - Thickening agents:

  • Following an NHS England safety alert, all starch based thickening agents have now been coded BLACK for new initiations, due to safety concerns. Prescribing for patients already established on starch based products should remain unchanged, but any new patients being initiated on thickening agents should be prescribed gum based preparations.

 

    
28/08/2018
   
news

July 2018 - Xailin night Eye Ointment:

  • Xailin Night Eye Ointment has been added to the CWS formulary with a GREEN colour coding. This can be prescribed as an alternative to Lacri-lube, which is currently experiencing manafacturing issues. It is a cost effective option with the added benefit of a 60 day expiry date after opening, compared to 30 days with Lacri-lube.

 

    
28/08/2018
   
news

June 2018 - Vitamin D guidance:

    
26/06/2018
   
news

June 2018 - Dekas vitamin products:

  • Dekas multivitamin products have been recoded as BLUE (from RED) to allow ongoing prescribing in primary care after initiation by a specialist.
    
19/06/2018
   
news

April 2018 - Gluten free prescribing:

  • In accordance with NHS England gluten free prescribing consultation recommendations, all gluten free products other than mixes and bread products are now non-formulary and are not to be prescribed.
    
23/04/2018
   
news

February 2018 - Freestyle Libre® proforma for GPs:

  • This proforma is designed to guide GPs to manage patient expectation, to have the set criteria listed to determine the suitability of FreeStyle Libre® and to determine if referral to secondary care for those who meet the criteria but are not under specialist care is appropriate.    

      Freestyle Libre® proforma

    
22/02/2018
   
news

January 2018 - Branded medicines:

    
22/02/2018
   
news

January 2018 - Specials booklet:

    
22/02/2018
   
news

December 2017 - Freestyle Libre®, CWS position statement:

    
10/01/2018
   
news

November 2017 - COPD guidelines:

    
10/01/2018
   
news October 2017 - Electronic cigarettes:
  • Until such time as NICE/Public Health publish guidelines and recommendations regarding the prescribing of electronic cigarettes, they will be coded as BLACK on CWS formulary    
    01/11/2017
  •    
    news August 2017 - Hydroxychloroquine recoding:
  • The recoding of hydroxychloroquine on our local formulary from amber to blue, was agreed at the July APC meeting. Therefore, shared care agreements are no longer required for this medicine.    
    13/09/2017
  •    
    news August 2017 - Shortage Of Adult Hepatitis B Vaccine
  • There is a global shortage of hepatitis B vaccine which is currently impacting severely on the UK supply. The situation is particularly critical during August but there is likely to still be some limitations on supply until early 2018. PHE have developed temporary recommendations to support clinicians undertaking an individual risk assessment to ensure that stock is available for those individuals at highest and most immediate risk of exposure to hepatitis B: Hepatitis B vaccine shortage news link    
    16/08/2017
  •    
    news June 2017 Pregabalin patent expiry neuropathic pain:
  • The 2015 court ruling to only prescribe pregabalin by brand when treating neuropathic pain is to be withdrawn following the patent for neuropathic pain expiring on 17th July 2017. Therefore pregabalin can now be prescribed generically for any indication. Click on the following link for further information: Pregabalin guidance    
    18/07/2017
  •    
    news May 2017 - Emollient savings by switching to alternative brands:
  • Epimax cream is a comparable product to Diprobase cream offering cost savings of 61% against Diprobase. Isomol gel is a comparable product to Doublebase gel offering cost savings of 50% against Doublebase. When initiating please consider the most cost effective product to meet your patients need and review existing repeat issues.    
    18/07/2017
  •    
    news April 2017 - Patient Safety Alert the risks to the unborn child in women taking valproate during pregnancy:
  • The MHRA and NHS Improvement issued a Patient Safety Alert to highlight the risks in pregnant women taking valproate to the unborn child and details the actions NHS organisations should take in order to minimise those risks. Go to the link below to see the full Patient Safety Alert: Resources to support safe use of valproate    
    18/07/2017
  •    
    news March 2017 - The new diabetes pathway has been agreed:
  • It is available to view on our formulary or by using the following link Adult type1 diabetic pathway    
    28/04/2017
  •    
    news March 2017 - NEW DRUG - Toujeo insulin glargine 300units/ml solution for injection in a pre-filled pen:
  • Specialist initiation only, after diabetes is not controlled by other insulins, or when other insulins are not tolerated. Must be prescribed by brand name and once daily dosing only. Coded on formulary as BLUE.     
    28/04/2017
  •    
    news March 2017 - NEW DRUG - Dulaglutide solution for injection in pre-filled pen/syringe:
  • This is a 3rd line treatment option for Type 2 diabetes, in line with NICE NG28 recommendations for glucagon-like peptide-1 receptor agonists. The device is patient friendly and suitable for needle phobic patients. Coded on for formulary as GREEN.     
    28/04/2017
  •    
    news March 2017 - ONS formulary review: The formulary has been simplified -
  • 1st line choices are the powders that can be mixed with water or milk.
  • 2nd line choices are the pre-mixed tetra packs. Oral Nutritional Supplements Formulary for Adults    
    28/04/2017
  •    
    news January 17 - Conflicts of Interest,NHS England Revised Guidance:
  • NHS England has issued new guidance around conflicts of interest. NHSE Conflict of Interest revised guidelines 2016    
    28/04/2017
  •    
    news January 2017 - Contraceptives being discontinued and the alternatives:
  • Ovysmen has been discontinued by the manufacturer. Brevinor is the only alternate brand for this formulation and strength of COC. The coding has been changed from Non-formulary to Green.
  • Micronor has been discontinued by the manufacturer. Noriday is the only alternate brand for this formulation and strength of norethisterone containing POP. The coding has been changed from Non-formulary to Green.     
    28/04/2017
  •    
    news May 2016 Area Prescribing Committee minutes now available to view, access via the Area Prescribing Committee section of this page.     
    22/07/2016
       
    news May 2016 - Change in formulary coding for anti-dementia drugs (donepezil, galantamine, rivastigmine, memantine)from amber to BLUE. New Information sheet available to support primary care prescriber responsibilities CWS Anti-dementia drugs BLUE coding information sheet    
    16/06/2016
       
    news April 2016 - New XGEVA (denosumab 120mg) ESCA: prevention of skeletal events in adults (over the age of 18 years) with bone metastasis from solid tumours (other than prostate) XGEVA (denosumab 120mg) ESCA    
    16/06/2016
       
    news April 2016 - New Tolcapone ESCA :motor fluctuations in idiopathic Parkinson's disease Tolcapone ESCA    
    16/06/2016
       
    news March 2015 APC - Insulin degludec was approved as a 3rd line option in poorly controlled diabetics. Coded as BLUE. Initiation must be undertaken by a Consultant Diabetologist. Please refer to March 2015 APC summary for further information. March 2015 APC Summary    
    29/04/2015
       
    news March 2014    
    03/04/2014
       
    news New Effective Shared care Agreement ESCA available: Sodium Oxybate Effective Shared Care    
    03/04/2014
       
    news 13th February 2014    
    13/02/2014
       
    news Published infections formulary section  
    13/02/2014
       
    news Published ear, nose, and oropharynx formulary section  
    13/02/2014
       
    news 20th January 2014    
    20/01/2014
       
    news Launched formulary app for android  
    20/01/2014
       
    news Launched formulary app for iPhone  
    20/01/2014
       
    news 10th December 2013    
    11/12/2013
       
    news Launched Antibiotic Guidelines Summary Leaflet  
    10/12/2013
       
    news Launched Antibiotic Guidelines for Primary Care 2013  
    06/12/2013
       

     

     

     

     


    netFormulary